Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Colorectal Cancer Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Colorectal Cancer 15
Colorectal Cancer Therapeutics under Development by Companies 17
Colorectal Cancer Therapeutics under Investigation by Universities/Institutes 26
Late Stage Products 45
Comparative Analysis 45
Mid Clinical Stage Products 46
Comparative Analysis 46
Early Clinical Stage Products 47
Comparative Analysis 47
Discovery and Pre-Clinical Stage Products 48
Comparative Analysis 48
Colorectal Cancer Therapeutics – Products under Development by Companies 49
Colorectal Cancer Therapeutics – Products under Investigation by Universities/Institutes 65
Companies Involved in Colorectal Cancer Therapeutics Development 114
Bristol-Myers Squibb Company 114
Johnson & Johnson 115
Boehringer Ingelheim GmbH 116
F. Hoffmann-La Roche Ltd. 117
Kyowa Hakko Kirin Co., Ltd. 118
Abbott Laboratories 119
Amgen Inc. 120
Sanofi-Aventis 121
Adherex Technologies Inc. 122
AstraZeneca PLC 123
Eli Lilly and Company 124
GlaxoSmithKline plc 125
Tekmira Pharmaceuticals Corp. 126
Genentech, Inc. 127
Nektar Therapeutics 128
Daiichi Sankyo Company, Ltd 129
Merck & Co., Inc. 130
Oxford BioMedica plc 131
YM BioSciences Inc. 132
Labopharm Inc. 133
Symphogen A/S 134
Light Sciences Oncology, Inc. 135
Celltrion, Inc. 136
Novartis AG 137
Aphios Corporation 138
ImClone Systems Incorporated 139
Cephalon, Inc. 140
Chong Kun Dang Pharmaceutical 141
Chugai Pharmaceutical Co. Ltd 142
Eisai Co., Ltd. 143
Human Genome Sciences, Inc. 144
Nippon Kayaku Co., Ltd. 145
OSI Pharmaceuticals, Inc. 146
Pfizer Inc. 147
Taiho Pharmaceutical Co., Ltd. 148
Yakult Honsha Co., Ltd. 149
Enzon Pharmaceuticals, Inc. 150
Bayer AG 151
Merck KGaA 152
4SC AG 153
Neogenix Oncology Corporation 154
Alchemia Limited 155
EntreMed, Inc. 156
Celldex Therapeutics, Inc. 157
Enzo Biochem, Inc. 158
IMMUNOMEDICS, INC 159
InNexus Biotechnology Inc. 160
Neuren Pharmaceuticals Limited 161
Novogen Limited 162
Oncolytics Biotech Inc. 163
Oncothyreon Inc 164
Compugen Ltd. 165
Critical Outcome Technologies Inc. 166
Keryx Biopharmaceuticals, Inc. 167
ARQULE, INC 168
Telik, Inc. 169
Poniard Pharmaceuticals, Inc. 170
Regeneron Pharmaceuticals, Inc. 171
Oncogenex Pharmaceuticals, Inc. 172
Dendreon Corporation 173
Transgene SA 174
Sirtex Medical Limited 175
Green Cross Corporation 176
MOLOGEN AG 177
Synta Pharmaceuticals Corp. 178
CrystalGenomics, Inc. 179
BioAlliance Pharma SA 180
NanoCarrier Co., Ltd. 181
Antisense Pharma GmbH 182
INSYS Therapeutics, Inc. 183
Philogen S.p.A. 184
Actis Biologics, Inc 185
Glycotope GmbH 186
immatics biotechnologies GmbH 187
Celator Pharmaceuticals, Inc. 188
MacroGenics, Inc. 189
ACT Biotech, Inc. 190
OncoMed Pharmaceuticals, Inc. 191
Boston Biomedical, Inc. 192
DanDrit Biotech A/S 193
Pivotal BioSciences, Inc. 194
Merrimack Pharmaceuticals, Inc. 195
Deciphera Pharmaceuticals, LLC 196
Jennerex Biotherapeutics, Inc. 197
MolMed S.p.A. 198
PhytoCeutica, Inc. 199
Syndax Pharmaceuticals, Inc. 200
NOXXON Pharma AG 201
Globeimmune, Inc. 202
Etubics Corporation 203
CG Therapeutics, Inc. 204
Kinex Pharmaceuticals, LLC 205
CureTech Ltd. 206
Biothera 207
Nereus Pharmaceuticals, Inc. 208
AVEO Pharmaceuticals, Inc. 209
Dynamix Pharmaceuticals Ltd. 210
Isofol Medical AB 211
Cytavis Biopharma GmbH 212
Medical Enzymes AG 213
Prologue Research International, Inc. 214
Therapure Biopharma Inc. 215
VectorLogics, Inc. 216
ISA Pharmaceuticals B.V. 217
Oncozyme Pharma Inc. 218
Colorectal Cancer – Therapeutics Assessment 219
Assessment by Monotherapy Products 219
Assessment by Combination Products 220
Assessment by Route of Administration 221
Assessment by Molecule Type 224
Drug Profiles 227
Perifosine - Drug Profile 227
Regorafenib - Drug Profile 228
HA-Irinotecan - Drug Profile 230
Eniluracil - Drug Profile 232
Angiozyme - Drug Profile 234
Avastin - Drug Profile 235
Afinitor - Drug Profile 237
IMC-1121B - Drug Profile 239
Davanat - Drug Profile 241
Vectibix - Drug Profile 243
Aptocine - Drug Profile 245
KRX-0401 + Xeloda - Drug Profile 247
MGN1703 - Drug Profile 248
Xeloda + Oxaliplatin - Drug Profile 250
FOLFOX + Vectibix - Drug Profile 252
MK-0646 + Cetuximab + Irinotecan - Drug Profile 254
Vectibix + FOLFIRI - Drug Profile 256
Recentin + FOLFOX - Drug Profile 258
Recentin + Xelox - Drug Profile 260
Eloxatin + Avastin + Leucovorin + Fluorouracil - Drug Profile 261
Eloxatin + Avastin + Capecitabine - Drug Profile 263
Fluorouracil + Leucovorin Calcium + CPT-11 - Drug Profile 265
CPT-11 + TS-1 - Drug Profile 266
Cetuximab + FOLFOX-4 - Drug Profile 267
Avastin + Irinotecan + Leucovorin + 5-Fluorouracil - Drug Profile 269
Imprime PGG + Erbitux - Drug Profile 271
Oxaliplatin + Leucovorin + 5-Fluorouracil - Drug Profile 273
Erbitux + FOLFIRI - Drug Profile 275
S-1 + Oxaliplatin + Bevacizumab - Drug Profile 277
S-1 + Oxaliplatin - Drug Profile 279
Tarceva - Drug Profile 281
Ramucirumab + FOLFIRI - Drug Profile 283
ZALTRAP + FOLFIRI - Drug Profile 285
Zaltrap - Drug Profile 287
FOLFIRI + Vectibix + Avastin - Drug Profile 289
FOLF(HA)Iri - Drug Profile 291
Aptocine + FOLFIRI - Drug Profile 293
Aptocine + FOLFOX4 - Drug Profile 295
Colorectal Cancer Therapeutics – Drug Profile Updates 297
Colorectal Cancer Therapeutics – Discontinued Products 311
Colorectal Cancer Therapeutics - Dormant Products 318
Colorectal Cancer – Product Development Milestones 353
Featured News & Press Releases 353
Appendix 361
Methodology 361
Coverage 361
Secondary Research 361
Primary Research 361
Expert Panel Validation 362
Contact Us 362
Disclaimer 362
List of Tables
Number of Products Under Development for Colorectal Cancer, H1 2012 18
Products under Development for Colorectal Cancer – Comparative Analysis, H1 2012 19
Number of Products under Development by Companies, H1 2012 21
Number of Products under Development by Companies, H1 2012 (Contd..1) 22
Number of Products under Development by Companies, H1 2012 (Contd..2) 23
Number of Products under Development by Companies, H1 2012 (Contd..3) 24
Number of Products under Development by Companies, H1 2012 (Contd..4) 25
Number of Products under Development by Companies, H1 2012 (Contd..5) 26
Number of Products under Development by Companies, H1 2012 (Contd..6) 27
Number of Products under Development by Companies, H1 2012 (Contd..7) 28
Number of Products under Investigation by Universities/Institutes, H1 2012 30
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 32
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 33
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 34
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 35
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 37
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 38
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 39
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 40
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 41
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 42
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 43
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 44
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 45
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 46
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 47
Comparative Analysis by Late Stage Development, H1 2012 48
Comparative Analysis by Mid Clinical Stage Development, H1 2012 49
Comparative Analysis by Early Clinical Stage Development, H1 2012 50
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 51
Products under Development by Companies, H1 2012 52
Products under Development by Companies, H1 2012 (Contd..1) 53
Products under Development by Companies, H1 2012 (Contd..2) 54
Products under Development by Companies, H1 2012 (Contd..3) 55
Products under Development by Companies, H1 2012 (Contd..4) 56
Products under Development by Companies, H1 2012 (Contd..5) 57
Products under Development by Companies, H1 2012 (Contd..6) 58
Products under Development by Companies, H1 2012 (Contd..7) 59
Products under Development by Companies, H1 2012 (Contd..8) 60
Products under Development by Companies, H1 2012 (Contd..9) 61
Products under Development by Companies, H1 2012 (Contd..10) 62
Products under Development by Companies, H1 2012 (Contd..11) 63
Products under Development by Companies, H1 2012 (Contd..12) 64
Products under Development by Companies, H1 2012 (Contd..13) 65
Products under Development by Companies, H1 2012 (Contd..14) 66
Products under Development by Companies, H1 2012 (Contd..15) 67
Products under Investigation by Universities/Institutes, H1 2012 68
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 69
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 70
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 71
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 72
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 73
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 74
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 75
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 76
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 77
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 78
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 79
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 80
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 81
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 82
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 83
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 84
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 85
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 86
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 87
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 88
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 89
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 90
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 91
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 92
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 93
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 94
Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 95
Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 96
Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 97
Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 98
Products under Investigation by Universities/Institutes, H1 2012 (Contd..31) 99
Products under Investigation by Universities/Institutes, H1 2012 (Contd..32) 100
Products under Investigation by Universities/Institutes, H1 2012 (Contd..33) 101
Products under Investigation by Universities/Institutes, H1 2012 (Contd..34) 102
Products under Investigation by Universities/Institutes, H1 2012 (Contd..35) 103
Products under Investigation by Universities/Institutes, H1 2012 (Contd..36) 104
Products under Investigation by Universities/Institutes, H1 2012 (Contd..37) 105
Products under Investigation by Universities/Institutes, H1 2012 (Contd..38) 106
Products under Investigation by Universities/Institutes, H1 2012 (Contd..39) 107
Products under Investigation by Universities/Institutes, H1 2012 (Contd..40) 108
Products under Investigation by Universities/Institutes, H1 2012 (Contd..41) 109
Products under Investigation by Universities/Institutes, H1 2012 (Contd..42) 110
Products under Investigation by Universities/Institutes, H1 2012 (Contd..43) 111
Products under Investigation by Universities/Institutes, H1 2012 (Contd..44) 112
Products under Investigation by Universities/Institutes, H1 2012 (Contd..45) 113
Products under Investigation by Universities/Institutes, H1 2012 (Contd..46) 114
Products under Investigation by Universities/Institutes, H1 2012 (Contd..47) 115
Products under Investigation by Universities/Institutes, H1 2012 (Contd..48) 116
Bristol-Myers Squibb Company, H1 2012 117
Johnson & Johnson, H1 2012 118
Boehringer Ingelheim GmbH, H1 2012 119
F. Hoffmann-La Roche Ltd., H1 2012 120
Kyowa Hakko Kirin Co., Ltd., H1 2012 121
Abbott Laboratories, H1 2012 122
Amgen Inc., H1 2012 123
Sanofi-Aventis, H1 2012 124
Adherex Technologies Inc., H1 2012 125
AstraZeneca PLC, H1 2012 126
Eli Lilly and Company, H1 2012 127
GlaxoSmithKline plc, H1 2012 128
Tekmira Pharmaceuticals Corp., H1 2012 129
Genentech, Inc., H1 2012 130
Nektar Therapeutics, H1 2012 131
Daiichi Sankyo Company, Ltd, H1 2012 132
Merck & Co., Inc., H1 2012 133
Oxford BioMedica plc, H1 2012 134
YM BioSciences Inc., H1 2012 135
Labopharm Inc., H1 2012 136
Symphogen A/S, H1 2012 137
Light Sciences Oncology, Inc., H1 2012 138
Celltrion, Inc., H1 2012 139
Novartis AG, H1 2012 140
Aphios Corporation, H1 2012 141
ImClone Systems Incorporated, H1 2012 142
Cephalon, Inc., H1 2012 143
Chong Kun Dang Pharmaceutical, H1 2012 144
Chugai Pharmaceutical Co. Ltd, H1 2012 145
Eisai Co., Ltd., H1 2012 146
Human Genome Sciences, Inc., H1 2012 147
Nippon Kayaku Co., Ltd., H1 2012 148
OSI Pharmaceuticals, Inc., H1 2012 149
Pfizer Inc., H1 2012 150
Taiho Pharmaceutical Co., Ltd., H1 2012 151
Yakult Honsha Co., Ltd., H1 2012 152
Enzon Pharmaceuticals, Inc., H1 2012 153
Bayer AG, H1 2012 154
Merck KGaA, H1 2012 155
4SC AG, H1 2012 156
Neogenix Oncology Corporation, H1 2012 157
Alchemia Limited, H1 2012 158
EntreMed, Inc., H1 2012 159
Celldex Therapeutics, Inc., H1 2012 160
Enzo Biochem, Inc., H1 2012 161
IMMUNOMEDICS, INC, H1 2012 162
InNexus Biotechnology Inc., H1 2012 163
Neuren Pharmaceuticals Limited, H1 2012 164
Novogen Limited, H1 2012 165
Oncolytics Biotech Inc., H1 2012 166
Oncothyreon Inc, H1 2012 167
Compugen Ltd., H1 2012 168
Critical Outcome Technologies Inc., H1 2012 169
Keryx Biopharmaceuticals, Inc., H1 2012 170
ARQULE, INC, H1 2012 171
Telik, Inc., H1 2012 172
Poniard Pharmaceuticals, Inc., H1 2012 173
Regeneron Pharmaceuticals, Inc., H1 2012 174
Oncogenex Pharmaceuticals, Inc., H1 2012 175
Dendreon Corporation, H1 2012 176
Transgene SA, H1 2012 177
Sirtex Medical Limited, H1 2012 178
Green Cross Corporation, H1 2012 179
MOLOGEN AG, H1 2012 180
Synta Pharmaceuticals Corp., H1 2012 181
CrystalGenomics, Inc., H1 2012 182
BioAlliance Pharma SA, H1 2012 183
NanoCarrier Co., Ltd., H1 2012 184
Antisense Pharma GmbH, H1 2012 185
INSYS Therapeutics, Inc., H1 2012 186
Philogen S.p.A., H1 2012 187
Actis Biologics, Inc, H1 2012 188
Glycotope GmbH, H1 2012 189
immatics biotechnologies GmbH, H1 2012 190
Celator Pharmaceuticals, Inc., H1 2012 191
MacroGenics, Inc., H1 2012 192
ACT Biotech, Inc., H1 2012 193
OncoMed Pharmaceuticals, Inc., H1 2012 194
Boston Biomedical, Inc., H1 2012 195
DanDrit Biotech A/S, H1 2012 196
Pivotal BioSciences, Inc., H1 2012 197
Merrimack Pharmaceuticals, Inc., H1 2012 198
Deciphera Pharmaceuticals, LLC, H1 2012 199
Jennerex Biotherapeutics, Inc., H1 2012 200
MolMed S.p.A., H1 2012 201
PhytoCeutica, Inc., H1 2012 202
Syndax Pharmaceuticals, Inc., H1 2012 203
NOXXON Pharma AG, H1 2012 204
Globeimmune, Inc., H1 2012 205
Etubics Corporation, H1 2012 206
CG Therapeutics, Inc., H1 2012 207
Kinex Pharmaceuticals, LLC, H1 2012 208
CureTech Ltd., H1 2012 209
Biothera, H1 2012 210
Nereus Pharmaceuticals, Inc., H1 2012 211
AVEO Pharmaceuticals, Inc., H1 2012 212
Dynamix Pharmaceuticals Ltd., H1 2012 213
Isofol Medical AB, H1 2012 214
Cytavis Biopharma GmbH, H1 2012 215
Medical Enzymes AG, H1 2012 216
Prologue Research International, Inc., H1 2012 217
Therapure Biopharma Inc., H1 2012 218
VectorLogics, Inc., H1 2012 219
ISA Pharmaceuticals B.V., H1 2012 220
Oncozyme Pharma Inc., H1 2012 221
Assessment by Monotherapy Products, H1 2012 222
Assessment by Combination Products, H1 2012 223
Assessment by Stage and Route of Administration, H1 2012 226
Assessment by Stage and Molecule Type, H1 2012 229
Colorectal Cancer Therapeutics – Drug Profile Updates 300
Colorectal Cancer Therapeutics – Discontinued Products 314
Colorectal Cancer Therapeutics – Discontinued Products (Contd..1) 315
Colorectal Cancer Therapeutics – Discontinued Products (Contd..2) 316
Colorectal Cancer Therapeutics – Discontinued Products (Contd..3) 317
Colorectal Cancer Therapeutics – Discontinued Products (Contd..4) 318
Colorectal Cancer Therapeutics – Discontinued Products (Contd..5) 319
Colorectal Cancer Therapeutics – Discontinued Products (Contd..6) 320
Colorectal Cancer Therapeutics – Dormant Products 321
Colorectal Cancer Therapeutics – Dormant Products (Contd..1) 322
Colorectal Cancer Therapeutics – Dormant Products (Contd..2) 323
Colorectal Cancer Therapeutics – Dormant Products (Contd..3) 324
Colorectal Cancer Therapeutics – Dormant Products (Contd..4) 325
Colorectal Cancer Therapeutics – Dormant Products (Contd..5) 326
Colorectal Cancer Therapeutics – Dormant Products (Contd..6) 327
Colorectal Cancer Therapeutics – Dormant Products (Contd..7) 328
Colorectal Cancer Therapeutics – Dormant Products (Contd..8) 329
Colorectal Cancer Therapeutics – Dormant Products (Contd..9) 330
Colorectal Cancer Therapeutics – Dormant Products (Contd..10) 331
Colorectal Cancer Therapeutics – Dormant Products (Contd..11) 332
Colorectal Cancer Therapeutics – Dormant Products (Contd..12) 333
Colorectal Cancer Therapeutics – Dormant Products (Contd..13) 334
Colorectal Cancer Therapeutics – Dormant Products (Contd..14) 335
Colorectal Cancer Therapeutics – Dormant Products (Contd..15) 336
Colorectal Cancer Therapeutics – Dormant Products (Contd..16) 337
Colorectal Cancer Therapeutics – Dormant Products (Contd..17) 338
Colorectal Cancer Therapeutics – Dormant Products (Contd..18) 339
Colorectal Cancer Therapeutics – Dormant Products (Contd..19) 340
Colorectal Cancer Therapeutics – Dormant Products (Contd..20) 341
Colorectal Cancer Therapeutics – Dormant Products (Contd..21) 342
Colorectal Cancer Therapeutics – Dormant Products (Contd..22) 343
Colorectal Cancer Therapeutics – Dormant Products (Contd..23) 344
Colorectal Cancer Therapeutics – Dormant Products (Contd..24) 345
Colorectal Cancer Therapeutics – Dormant Products (Contd..25) 346
Colorectal Cancer Therapeutics – Dormant Products (Contd..26) 347
Colorectal Cancer Therapeutics – Dormant Products (Contd..27) 348
Colorectal Cancer Therapeutics – Dormant Products (Contd..28) 349
Colorectal Cancer Therapeutics – Dormant Products (Contd..29) 350
Colorectal Cancer Therapeutics – Dormant Products (Contd..30) 351
Colorectal Cancer Therapeutics – Dormant Products (Contd..31) 352
Colorectal Cancer Therapeutics – Dormant Products (Contd..32) 353
Colorectal Cancer Therapeutics – Dormant Products (Contd..33) 354
Colorectal Cancer Therapeutics – Dormant Products (Contd..34) 355
List of Figures
Number of Products under Development for Colorectal Cancer, H1 2012 18
Products under Development for Colorectal Cancer – Comparative Analysis, H1 2012 19
Products under Development by Companies, H1 2012 20
Products under Investigation by Universities/Institutes, H1 2012 29
Late Stage Products, H1 2012 48
Mid Clinical Stage Products, H1 2012 49
Early Clinical Stage Products, H1 2012 50
Discovery and Pre-Clinical Stage Products, H1 2012 51
Assessment by Monotherapy Products, H1 2012 222
Assessment by Combination Products, H1 2012 223
Assessment by Route of Administration, H1 2012 224
Assessment by Stage and Route of Administration, H1 2012 225
Assessment by Molecule Type, H1 2012 227
Assessment by Stage and Molecule Type, H1 2012 228